Hooda N, Suh M, Bylsma LC, Kelsh M. A systematic literature review of the association between dose reduction of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and survival in patients with HR-positive breast cancer (BC). Poster 1882eP, European Society for Medical Oncology (ESMO) Congress 2026, Madrid, Spain, October 23-27, 2026.

View Abstract

Bylsma L, Kelsh M, Jiang X, Mitchell M, Movva N, Sacks NC. To be or not to be a rare disease: An evaluation of prevalence estimates for cancers near the orphan status threshold. Poster O-008, National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, Washington, DC, October 25-27, 2026.

View Abstract